Get the Stockscreener App
3.535
4.29%
0.155
Perspective Therapeutics Inc stock is traded at $3.535, with a volume of 341.08K.
It is up +4.29% in the last 24 hours and down -18.21% over the past month.
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
See More
Previous Close:
$3.38
Open:
$3.34
24h Volume:
341.08K
Relative Volume:
0.30
Market Cap:
$262.52M
Revenue:
$6.96M
Net Income/Loss:
$-46.51M
P/E Ratio:
-20.60
EPS:
-0.1716
Net Cash Flow:
$-37.99M
1W Performance:
-9.62%
1M Performance:
-18.21%
6M Performance:
+27.72%
1Y Performance:
-76.99%
1-Day Range:
$3.28
$3.54
1-Week Range:
$3.28
$3.93
52-Week Range:
$1.60
$16.55
Perspective Therapeutics Inc Stock (CATX) Company Profile
Name
Perspective Therapeutics Inc
Sector
Industry
Phone
509-375-1202
Address
350 Hills Street, Suite 106, Richland
Compare CATX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
3.535 | 274.03M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
132.66 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
105.58 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
385.77 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
91.64 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
81.54 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | H.C. Wainwright | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-01-24 | Initiated | Wedbush | Outperform |
| Sep-25-24 | Initiated | Truist | Buy |
| Jul-25-24 | Initiated | BofA Securities | Buy |
| May-09-24 | Initiated | Cantor Fitzgerald | Overweight |
View All
Perspective Therapeutics Inc Stock (CATX) Latest News
Perspective Therapeutics Reports Promising Study Results at ASCO - MSN
Does Perspective Therapeutics Inc. fit your quant trading modelPortfolio Risk Summary & Real-Time Chart Pattern Alerts - Newser
Volume spikes in Perspective Therapeutics Inc. stock – what they meanDividend Hike & Safe Capital Growth Stock Tips - Newser
What technical models suggest about Perspective Therapeutics Inc.’s comebackPortfolio Update Report & High Yield Stock Recommendations - Newser
How Perspective Therapeutics Inc. stock performs during market volatilityCPI Data & Stock Market Timing Techniques - Newser
Can Perspective Therapeutics Inc. hit a new high this monthCEO Change & Free Community Consensus Stock Picks - Newser
How to read the order book for Perspective Therapeutics Inc.July 2025 Weekly Recap & Reliable Intraday Trade Plans - Newser
Perspective Therapeutics price target raised to $16 from $15 at RBC Capital - MSN
Short Interest Drops in Perspective Therapeutics Inc. After RallyMarket Movers & Target Return Focused Stock Picks - sundaytimes.kr
Perspective Therapeutics Inc. Could See a Relief Rally From SupportMarket Risk Summary & Safe Swing Trade Setups - newsimpact.co.kr
Perspective Therapeutics: Q2 Earnings Snapshot - Greenwich Time
Perspective Therapeutics Posts Q2 2025 Earnings, Highlights Clinical Progress and Financial Stability - AInvest
Perspective Therapeutics Reports Q2 2025 Progress and Financials - TipRanks
Oppenheimer Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Cuts Target Price to $14 - 富途牛牛
Oppenheimer lowers Perspective Therapeutics stock price target to $14 - Investing.com India
Gain Therapeutics, Inc. shares rise 3.27% intraday after Perspective Therapeutics presented positive [212Pb]VMT-α-NET study update at ASCO Annual Meeting. - AInvest
Perspective Therapeutics reports Q2 EPS (29c), consensus (29c) - TipRanks
Perspective Therapeutics: Navigating the Theranostics Frontier with Precision and Purpose - AInvest
Perspective Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Perspective Therapeutics Q2 Loss: $21.5M, Aligns with ForecastNews and Statistics - IndexBox
Perspective Therapeutics Reports Q2 Loss - Mitrade
Perspective Therapeutics earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
Perspective Therapeutics Inc (CATX) Q2 2025 Earnings: EPS Loss o - GuruFocus
Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results - The Manila Times
CATX 8-K: Q2 2025 results released; corporate deck updated - Stock Titan
Cancer Drug Developer Perspective Sees Treatment Success: 4 of 7 Patients Respond in Phase 1/2a Trial - Stock Titan
What to do if you’re stuck in Perspective Therapeutics Inc.2025 Volume Leaders & AI Powered Trade Plan Recommendations - Newser
Perspective Therapeutics Q2 2025 Earnings Preview - MSN
Perspective Therapeutics Q2 Earnings Preview: Analysts Expect Losses and Revenue Decline - AInvest
Technical Models Suggest Perspective Therapeutics Inc. May Rebound SoonFree Group Entry - beatles.ru
What makes Perspective Therapeutics Inc. stock price move sharplyFree Trend Analysis for Safer Trades - Newser
Multi factor analysis applied to Perspective Therapeutics Inc.Free Value Investing Picks With Stability - Newser
Perspective Therapeutics (CATX) Projected to Post Earnings on Wednesday - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Ranking Perspective Therapeutics Inc. among high performing stocks via toolsFree Risk Controlled Short Term Trade Plans - Newser
Perspective Therapeutics, Inc. shares rise 3.09% after-hours following a corporate update on clinical progress and strategic positioning. - AInvest
Published on: 2025-08-04 12:18:12 - Jammu Links News
When is Perspective Therapeutics Inc. stock expected to show significant growthInvest smarter with expert stock recommendations - Jammu Links News
Why is Perspective Therapeutics Inc. stock attracting strong analyst attentionConsistent triple returns - Jammu Links News
What are the technical indicators suggesting about Perspective Therapeutics Inc.Unlock your portfolio’s hidden potential - Jammu Links News
How does Perspective Therapeutics Inc. generate profit in a changing economyBuild wealth steadily with proven methods - Jammu Links News
What are the latest earnings results for Perspective Therapeutics Inc.Unlock rapid growth potential in your portfolio - Jammu Links News
How many analysts rate Perspective Therapeutics Inc. as a “Buy”Build a strong portfolio for long-term success - Jammu Links News
Perspective Therapeutics: Giving Us Some Valuable Perspective On Alpha Emitter Therapy - Seeking Alpha
Perspective Therapeutics (NYSE:CATX) vs. Motus GI (NASDAQ:MOTS) Critical Contrast - Defense World
Perspective Therapeutics Updates Radiopharmaceutical Platform Presentation - TipRanks
Live market analysis of Perspective Therapeutics Inc.Predictive AI Engine for Smart Investing - Newser
Applying chart zones and confluence areas to Perspective Therapeutics Inc.Short-Term AI-Based Stock Price Forecast - Newser
When is the best time to exit Perspective Therapeutics Inc.Smart Trade Mapping with Entry Details - Newser
How strong is Perspective Therapeutics Inc. company’s balance sheetTop Growth Tips For Consistent Profits - jammulinksnews.com
Perspective Therapeutics Inc Stock (CATX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.70%
0.34%
Cap:
|
Volume (24h):